Principles of care for acquired hemophilia

To establish clear priorities for the care of patients with acquired hemophilia A (AHA) by proposing 10 key principles of practical, holistic AHA management.

[1]  W. Sperr,et al.  Emicizumab for the treatment of acquired hemophilia A. , 2020, Blood.

[2]  P. Giangrande,et al.  International recommendations on the diagnosis and treatment of acquired hemophilia A , 2020, Haematologica.

[3]  Amogh M Joshi,et al.  Utilization of Emicizumab in Acquired Factor VIII Deficiency , 2020, The American journal of case reports.

[4]  P. Knöbl,et al.  Bleeding and Response to Hemostatic Therapy in Acquired Hemophilia A (AHA): Results from the GTH-AH 01/2010 Study. , 2020, Blood.

[5]  M. Desborough,et al.  Acquired haemophilia A treated with recombinant porcine factor VIII: a single centre UK experience , 2020, British journal of haematology.

[6]  C. Königs,et al.  Cross‐reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: Data from the GTH‐AH 01/2010 Study , 2020, Journal of thrombosis and haemostasis : JTH.

[7]  P. Giangrande,et al.  Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: A global expert consensus statement , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  Ammar Eljack,et al.  Emicizumab Use in Treatment of Acquired Hemophilia A: A Case Report , 2019, The American journal of case reports.

[9]  M. Streiff,et al.  Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention , 2019, Research and practice in thrombosis and haemostasis.

[10]  M. Spannagl,et al.  Emicizumab in the Treatment of Acquired Haemophilia: A Case Report , 2019, Transfusion Medicine and Hemotherapy.

[11]  P. Knöbl.  Prevention and Management of Bleeding Episodes in Patients with Acquired Hemophilia A , 2018, Drugs.

[12]  S. Nair,et al.  Principles of haemophilia care: The Asia‐Pacific perspective , 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

[13]  O. Christophe,et al.  Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? , 2017, Blood.

[14]  C. Leissinger,et al.  Acquired hemophilia A: Updated review of evidence and treatment guidance , 2017, American journal of hematology.

[15]  2017 Clinical trials update: Innovations in hemophilia therapy , 2017, American journal of hematology.

[16]  K. Gomez,et al.  Use of an innovative syringe pump to deliver bolus rFVIIa for patients with haemophilia and inhibitors undergoing surgery , 2017 .

[17]  M. Sholzberg,et al.  Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[18]  C. Kessler,et al.  Acquired haemophilia: an overview for clinical practice , 2015, European journal of haematology.

[19]  C. Leissinger,et al.  Acquired hemophilia A: emerging treatment options , 2015, Journal of blood medicine.

[20]  E. Gomperts,et al.  Efficacy and safety of OBI‐1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[21]  R. Greil,et al.  Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study. , 2015, Blood.

[22]  A. Tiede,et al.  Laboratory Diagnosis of Acquired Hemophilia A: Limitations, Consequences, and Challenges , 2014, Seminars in Thrombosis & Hemostasis.

[23]  S. Araf,et al.  An unusual cause of a haemorrhagic stroke: acquired haemophilia A , 2013, BMJ Case Reports.

[24]  J. Goudemand,et al.  Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l'Hémophilie Acquise) registry , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[25]  M. Makris,et al.  The World Federation of Hemophilia guideline on management of haemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[26]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[27]  H. Schwarz,et al.  Factor Eight Inhibitor Bypassing Activity , 2012 .

[28]  D. Cooper,et al.  Barriers to effective diagnosis and management of a bleeding patient with undiagnosed bleeding disorder across multiple specialties: results of a quantitative case-based survey , 2012, Journal of multidisciplinary healthcare.

[29]  F. Pellegrini,et al.  Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). , 2012, Blood.

[30]  F. Pellegrini,et al.  Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. , 2012, Blood.

[31]  J. Esser,et al.  Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) , 2012, Journal of thrombosis and haemostasis : JTH.

[32]  P. Collins,et al.  Management of acquired haemophilia A , 2011, Journal of thrombosis and haemostasis : JTH.

[33]  C. Kessler,et al.  Consensus recommendations for the diagnosis and treatment of acquired hemophilia A , 2010, BMC Research Notes.

[34]  J. Oldenburg,et al.  Genetic markers in acquired haemophilia , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[35]  P. Collins,et al.  Advances in the understanding of acquired haemophilia A: implications for clinical practice , 2010, British journal of haematology.

[36]  C. Kessler,et al.  International recommendations on the diagnosis and treatment of patients with acquired hemophilia A , 2009, Haematologica.

[37]  S. Seremetis,et al.  Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[38]  T. Baglin,et al.  Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. , 2007, Blood.

[39]  J. Astermark,et al.  A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. , 2007, Blood.

[40]  G. Mariani,et al.  Acquired hemophilia A: A concise review , 2005, American journal of hematology.

[41]  S. Sallah.  Treatment of acquired haemophilia with factor eight inhibitor bypassing activity , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[42]  J. Delgado,et al.  Acquired Haemophilia: Review and Meta‐Analysis Focused on Therapy and Prognostic Factors , 2003, British journal of haematology.

[43]  C. Négrier,et al.  The Treatment of Bleeding in Acquired Haemophilia with Recombinant Factor VIIa: A Multicentre Study , 1997, Thrombosis and Haemostasis.

[44]  A. Rademaker,et al.  A Prospective, Randomized Trial of Prednisone and Cyclophosphamide in the Treatment of Patients with Factor VIII Autoantibodies , 1993, Thrombosis and Haemostasis.

[45]  C. Kitchens,et al.  Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. , 1987, Archives of internal medicine.